Vimarsana
Biggest News Aggregation in the World

Page 6 - Yelin Jun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Yelin Jun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Yelin Jun Today - Breaking & Trending Today

GC Biopharma to Present New Data on Trends in Varicella Incidence Cases with Complications Among Korean Children at the 2022 ICPE - Vimarsana News

GC Biopharma to Present New Data on Trends in Varicella Incidence Cases with Complications Among Korean Children at the 2022 ICPE

Cases of Varicella infections have fallen by 92% in 10 years Studies implies that the one-dose universal varicella vaccination program in Korea since 2005 has been successful in preventing chickenpox GC

CORRECTING and REPLACING GC Pharma Receives Complete Response Letter From the U.S. FDA For 'GC5107' - Vimarsana News

CORRECTING and REPLACING GC Pharma Receives Complete Response Letter From the U.S. FDA For 'GC5107'

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO' - Vimarsana News

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107' - Vimarsana News

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Press release content from Business Wire. The AP news staff was not involved in its creation. GC Pharma Submits Biologics License Application to US FDA for Immune Globulin ‘GC5107’ February 26, 2021 GMT YONGIN, South Korea--(BUSINESS WIRE)--Feb 25, 2021-- GC Pharma (006280.KS) today announced that it had submitted its Biologics License Application (BLA) for ‘GC5107’ (Immune Globulin Intravenous (Human),10% Liquid) to the United States Food and Drug Administration (FDA). GC Pharma demonstrated positive results in a Phase III study in North America, meeting its primary efficacy endpoint...

Source: apnews.com